Phase III clinical trial - Sein métastatique RH+

DESTINY-Breast06 (D9670C00001)
Sein métastatique RH+
Ouvert depuis le: 12.02.2021
Site: Paris
Ouvert depuis le: 05.20.2021
Site: Saint-Cloud
Public cible
Adulte
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator·s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
Description de l'essai

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.